Nektar Therapeutics (NKTR) R&D chief sells shares to cover RSU tax

Rhea-AI Filing Summary

Nektar Therapeutics' Chief R&D Officer Jonathan Zalevsky reported a small share sale primarily for tax purposes. On May 19, 2026, he sold 199 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations linked to vesting restricted stock units. The filing states this did not represent a discretionary trade. Following the transaction, he directly held 20,975 shares of Nektar Therapeutics common stock.

Insider Trade Summary

Net Seller: 199 shares ($13,036)

Net Sell 1 txn

Insider Zalevsky Jonathan

Role Chief R&D Officer

Sold 199 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	199	$65.51	$13K

Holdings After Transaction: Common Stock — 20,975 shares (Direct, null)

Footnotes (1)

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 199 shares Weighted average sale price: $65.51 per share Post-transaction holdings: 20,975 shares +1 more

4 metrics

Shares sold 199 shares Common Stock sold on May 19, 2026

Weighted average sale price $65.51 per share Open-market sale to cover tax withholding

Post-transaction holdings 20,975 shares Common Stock directly held after sale

Trade price range $64.88–$68.43 per share Range of individual trades on May 19, 2026

Key Terms

RSUs, tax withholding obligations, weighted average sale price, open-market sale

4 terms

RSUs financial

"in connection with the vesting of the RSUs held by the reporting"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"sold by the reporting person to cover required tax withholding obligations"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zalevsky Jonathan

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S		199(1)	D	$65.51(2)	20,975	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nektar Therapeutics (NKTR) report for Jonathan Zalevsky?

Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky sold 199 shares of common stock. The sale occurred on May 19, 2026 and was tied to covering tax withholding from vesting RSUs, rather than a discretionary open-market trade.

At what price were Jonathan Zalevsky’s NKTR shares sold in this Form 4?

The 199 Nektar Therapeutics shares were sold at a weighted average price of $65.51 per share. The trades were executed in multiple transactions between $64.88 and $68.43, according to the Form 4 footnote disclosure.

Why did Jonathan Zalevsky sell Nektar Therapeutics (NKTR) shares in this filing?

The Form 4 states the sale was made solely to cover required tax withholding obligations from vesting RSUs. It explicitly notes the transaction does not represent a discretionary trade by Jonathan Zalevsky, indicating a mechanistic tax-related sale.

How many Nektar Therapeutics shares does Jonathan Zalevsky hold after this Form 4 sale?

After the reported transaction, Jonathan Zalevsky directly holds 20,975 shares of Nektar Therapeutics common stock. This post-transaction balance is disclosed in the Form 4 and provides context on his remaining equity position following the 199-share sale.

Was Jonathan Zalevsky’s NKTR share sale executed in a single trade or multiple trades?

The Form 4 notes that the transaction was executed in multiple trades. Prices ranged from $64.88 to $68.43 per share, with the reported $65.51 figure representing the weighted average sale price across those individual trades.